Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.42 EUR
Change Today -0.032 / -7.16%
Volume 10.0
ONY On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 2:25 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONY) Snapshot

Open
€0.45
Previous Close
€0.45
Day High
€0.46
Day Low
€0.39
52 Week High
03/3/15 - €1.22
52 Week Low
10/13/14 - €0.28
Market Cap
47.1M
Average Volume 10 Days
1.2K
EPS TTM
--
Shares Outstanding
113.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONY)

oncolytics biotech inc (ONY) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONY) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONY) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

Founded in 1998

oncolytics biotech inc (ONY) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: C$538.0K
Chief Financial Officer
Total Annual Compensation: C$284.2K
Chief Operating Officer and Director
Total Annual Compensation: C$370.5K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: $316.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $143.0K
Compensation as of Fiscal Year 2014.

oncolytics biotech inc (ONY) Key Developments

Oncolytics Biotech Inc. Announces Series of Oral and Poster Presentations at 9th International Conference in Boston Ma

Oncolytics Biotech Inc. announced that a series of oral and poster presentations are being made by the company's research collaborators at the 9th International Conference on Oncolytic Virus Therapeutics being held from June 13th to 16th, 2015 in Boston MA. Dr. Richard Vile is making an oral presentation regarding previously disclosed findings around augmenting tumor-specific natural killer (NK) responses and specifically attenuating tumor-specific immunosuppression. These data also suggest that the combination of PD-1 inhibition therapy with reovirus oncolytic/immunotherapy represents a readily translatable method to enhance the therapeutic efficacy. The first abstract/poster titled "Targeting peripheral and lymph node resistant CLL with combination reovirus therapy," was authored by Melcher, et al. The authors studied chronic lymphocytic leukemia ("CLL") and the problems associated with eradicating minimal residual disease and drug resistance. They concluded that the combination of reovirus and ABT-263 could increase direct and immune-mediated killing of peripheral disease and that reovirus in combination with Fludarabine may be useful in targeting drug-resistant lymph node disease. The second abstract/poster titled "Oncolysis by reovirus as an immune priming mechanism with VSV-cDNA immunological boosting treats large established tumors," was authored by Melcher, et al. The authors looked at the treatment of established B16 melanoma tumors in a mouse model. They concluded that the local killing of cancer cells by one virus primed the immune system and, by using tumor antigens expressed from a second virus, it was possible to generate potent immunological responses that led to the rejection of well established tumors. The third abstract/poster titled "Monocyte carriage and delivery of reovirus-antibody complexes for melanoma oncolysis," was authored by Melcher, et al. The authors studied preexisting antiviral immunity and found evidence that there is an alternative mechanism by which systemically administered reovirus may gain access to tumors, even in the presence of neutralizing antibodies.

Oncolytics Biotech Inc. - Shareholder/Analyst Call

To discuss recent progress in the development of REOLYSIN as a potential cancer therapeutic

Oncolytics Biotech Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors

Oncolytics Biotech Inc. announced that submission to the U.S. Food and Drug Administration for review, the Investigational New Drug Application containing the protocol titled MC1472: Phase 1 Study of Replication Competent Reovirus (REOLYSIN) in Combination with GM-CSF in Pediatric Patients with Relapsed or Refractory Brain Tumors is now active. The study is an open-label Phase I trial to clarify the safety, and determine possible efficacy, of GM-CSF given prior to administration of intravenous REOLYSIN for children with malignant high grade brain tumors. GM-CSF will be administered on days one and two of each cycle with REOLYSIN administered on days three, four and five. Cycles will be given every 28 days for up to 12 cycles if patients remain without evidence of tumor progression and without intolerable toxicity. The primary outcome for the nine to 18 patients of the Phase 1 study will be safety and tolerability. Secondary goals include median progression free and overall survival in this patient population.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONY:GR €0.42 EUR -0.032

ONY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONY.
View Industry Companies
 

Industry Analysis

ONY

Industry Average

Valuation ONY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.